Naturhouse Health (XMAD:NTH) YoY EBITDA Growth: -12.38% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:NTH Naturhouse Health SA XMAD:NTH
72 GF Score
Price €2.54
GF Value €1.62
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Naturhouse Health YoY EBITDA Growth?

Naturhouse Health XMAD:NTH +0.40% 72 YoY EBITDA Growth is -12.38% as of Dec. 2025. GuruFocus rates XMAD:NTH with a GF Score™ of 72/100 and a GF Value™ of €1.62 (Significantly Overvalued). The stock has 6 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Naturhouse Health's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was -12.38%.

Naturhouse Health's EBITDA per Share for the six months ended in Dec. 2025 was €0.09.

Naturhouse Health YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Naturhouse Health's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Naturhouse Health YoY EBITDA Growth Chart

Naturhouse Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.61 -25.07 17.31 -14.43 -4.60

Naturhouse Health Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.11 -16.58 -11.02 0.00 -12.38
XMAD:NTH
72GF Score
Naturhouse Health SA XMAD:NTH
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Naturhouse Health YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Naturhouse Health's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(0.249-0.261)/ | 0.261 |
=-4.60 %

Naturhouse Health's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(0.092-0.105)/ | 0.105 |
=-12.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -12.38% mean?
Naturhouse Health (XMAD:NTH) has a YoY EBITDA Growth of -12.38% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Naturhouse Health and its competitors.
Is Naturhouse Health's YoY EBITDA Growth too high?
Naturhouse Health's current YoY EBITDA Growth is -12.38%. Overall, Naturhouse Health has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Naturhouse Health's YoY EBITDA Growth compare to KHC and GIS?
Naturhouse Health's YoY EBITDA Growth of -12.38% can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Consumer Packaged Goods company?
A good YoY EBITDA Growth depends on the Consumer Packaged Goods industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Naturhouse Health and its competitors. Naturhouse Health's current YoY EBITDA Growth is -12.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturhouse Health stock overvalued right now?
Based on GuruFocus' analysis, Naturhouse Health (XMAD:NTH) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.62, compared to a current price of €2.54 — trading 56.8% above its estimated fair value. The current YoY EBITDA Growth is -12.38%. Naturhouse Health's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Naturhouse Health (XMAD:NTH), the current YoY EBITDA Growth is -12.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Naturhouse Health (XMAD:NTH) Overvalued in 2026?

Based on GuruFocus' analysis, Naturhouse Health stock appears to be overvalued. The current stock price of €2.54 is trading 56.8% above its estimated GF Value™ of €1.62. GuruFocus considers Naturhouse Health to be Significantly Overvalued.

Key valuation signals for XMAD:NTH:

  • YoY EBITDA Growth: -12.38%
  • GF Value™: €1.62 vs. price of €2.54 (56.8% above fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the XMAD:NTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Naturhouse Health Business Description

Other Exchanges 0R9G:UK2NH:Germany
Address Calle Claudio Coello, 91, 4º Planta, Madrid, ESP, 28006
Naturhouse Health SA provides nutrition & weight management products. The activity of the company is the export, wholesale, and retail sales of all kinds of products related to dietetics, herbal remedies, and natural cosmetics, as well as the preparation, promotion, creation, edition, dissemination, sale, and distribution of all kinds of magazines, books, and brochures and the marketing of dietary products, herbal remedies, and natural cosmetics. This activity is mainly carried out through franchisees and its stores. The geographical segments of the company are Spain, France, Italy, Poland, and Other countries.
72GF Score

Get the complete analysis for XMAD:NTH

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.54
Price
€1.62
GF Value